ARTICLE | Company News
Complete response for GSK's Avodart
January 28, 2011 1:56 AM UTC
FDA issued a complete response for an sNDA from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for Avodart dutasteride to reduce the risk of prostate cancer in men at increased risk of the disease. GSK would not disclose the contents of the letter but said it plans to meet with FDA. ...